Breaking News
April 19, 2019 - New insights into how vitamin D affects immune system
April 19, 2019 - Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
April 19, 2019 - Exercise can improve non-motor symptoms of Parkinson’s disease
April 19, 2019 - KZFPs play a key role in the regulation of human genome
April 19, 2019 - Extracts of ginkgo seeds show antibacterial activity on pathogens that cause skin infections
April 19, 2019 - Exercises and swimming goggles may reduce adverse effects on eye during long spaceflights
April 19, 2019 - Review suggests a reciprocal relationship between obesity and self-control
April 19, 2019 - Study identifies how enterococci bacteria cause antibiotic-resistant bloodstream infections
April 19, 2019 - Triple negative breast cancer develop resistance to chemotherapy by turning on molecular pathway
April 19, 2019 - Researchers identify key clues to brain and pancreas development
April 19, 2019 - Metformin May Cut Risk for Prematurity, Miscarriage in PCOS
April 19, 2019 - Obese mouse mothers trigger heart problems in offspring
April 19, 2019 - Research sheds light on how leukemia cells become resistant to drugs
April 19, 2019 - Health Tip: Stopping Nosebleeds – Drugs.com MedNews
April 19, 2019 - Pediatric endocrinologist gives iconic ‘Mona Lisa’ a second medical opinion
April 19, 2019 - Tapping patients’ wisdom for C-section pain management
April 18, 2019 - Why have autism rates ‘exploded’ in New Jersey?
April 18, 2019 - Microbiome science may help doctors to improve treatment for children with IBS
April 18, 2019 - New gene therapy cures babies with fatal ‘Bubble Boy’ disease
April 18, 2019 - No female mice? Scientists may still approve NIH grant
April 18, 2019 - What needs to be said about mental health in medicine
April 18, 2019 - Hickenlooper Expanded Medicaid, Created State-Run Marketplace To Insure Nearly All Coloradans
April 18, 2019 - Cancer cells grown in tumor-mimicking environment can help predict the effect of experimental drugs
April 18, 2019 - Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH
April 18, 2019 - Adhesive gel bonds to eye surface, could repair injuries without surgery
April 18, 2019 - The future of genomics: A podcast featuring Stanford geneticists
April 18, 2019 - As Syphilis Invades Rural America, A Fraying Health Safety Net Is Failing To Stop It
April 18, 2019 - APOE gene impacts sleep depending on gender and severity of Alzheimer’s
April 18, 2019 - PCORI’s newly approved awards focus on cancer pain and opioid use disorders
April 18, 2019 - New tool provides a standard way to measure effects of caring for survivors of TBI
April 18, 2019 - Smartphone use risks eye examination misdiagnosis
April 18, 2019 - How drug-resistant bugs grow in CF patients’ lungs
April 18, 2019 - Gordana Vunjak-Novakovic Elected to American Academy of Arts & Sciences
April 18, 2019 - Podcast: KHN’s ‘What The Health?’ You Have Questions, We Have Answers
April 18, 2019 - Diabetic drug shows potential to be repurposed as heart disease treatment for non-diabetic patients
April 18, 2019 - New estimation method assesses natural variations in sex ratio at birth
April 18, 2019 - UTA scientist receives $1.17 million grant for cancer research
April 18, 2019 - Coagulation factor VIIa prevents bleeds in hemophilia animal models
April 18, 2019 - Researchers identify risk factors for severe infection after knee replacement
April 18, 2019 - Mass drug administration can offer community-level protection against malaria
April 18, 2019 - FDA’s added sugar label could have substantial health and cost-saving benefits
April 18, 2019 - Researchers identify cause of inherited metabolic disorder
April 18, 2019 - Single strip of white paint not sufficient to protect people who ride bikes
April 18, 2019 - Partner status influences link between sexual problems and self-efficacy in breast cancer survivors
April 18, 2019 - Colorectal Neoplasia Risk Up for Hodgkin Lymphoma Survivors
April 18, 2019 - Rigid spine muscular dystrophy – Genetics Home Reference
April 18, 2019 - Simple bile acid blood test could tell risk of stillbirth
April 18, 2019 - Center for Experimental Therapeutics aims to enable all steps of drug development | News Center
April 18, 2019 - Falling for telephone scams could be an early sign of dementia
April 18, 2019 - Researchers annotate key neuronal proteins in lamprey genome
April 18, 2019 - Study uncovers new biomarker for personalized cancer treatments
April 18, 2019 - Scientists enter research collaboration to find a cure for cancer
April 18, 2019 - Study to compare benefits of tai chi and mindfulness meditation on MS symptoms
April 18, 2019 - Gestational diabetes during pregnancy may increase risk of type 1 diabetes in children
April 18, 2019 - Maternal age has no effect on IVF success, conclude researchers
April 18, 2019 - Is a New Remedy for Body Odor on the Horizon?
April 18, 2019 - Orthostatic hypotension – Genetics Home Reference
April 18, 2019 - Healing the heartbreak of stillbirth and newborn death
April 18, 2019 - New study calls healthiness of eggs into question
April 18, 2019 - Conference to highlight advances in human immune monitoring, bioinformatics | News Center
April 18, 2019 - Bacteria use viruses for self-recognition, study reveals
April 18, 2019 - New adhesive patch could help reduce post-heart attack muscle damage
April 18, 2019 - Researchers analyze the effects of dark play in a serious video game
April 18, 2019 - Scientists revive pig brain cells four hours after death
April 18, 2019 - Filial cannibalism and offspring abandonment may be forms of parental care
April 18, 2019 - Two proteins act in concert to maintain a healthy heart in mice, shows study
April 18, 2019 - Scientists create a functioning 3D printed heart
April 18, 2019 - Non-invasive vagus nerve stimulation improves disease symptoms in patients with rheumatoid arthritis
April 18, 2019 - Majority of men struggle to understand diagnosis and treatment of prostate cancer
April 18, 2019 - Researchers create new small molecules that may combat equine encephalitis viruses
April 18, 2019 - Animal-assisted therapy improves social behavior in patients with brain injuries
April 18, 2019 - Some viruses help protect harmful bacteria in CF patients | News Center
April 18, 2019 - Outpatient healthcare providers inappropriately prescribe antibiotics to 40% of patients
April 18, 2019 - Men who have a resting heart rate of 75 bpm are twice as likely to die early
April 18, 2019 - Novel serum biomarkers to detect NAFLD-related fibrosis
April 18, 2019 - New study delves deeper into individual genomic differences than ever before
April 18, 2019 - Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients
April 18, 2019 - Emotional mirror neurons found in rats
April 18, 2019 - Sylvia Plevritis appointed chair of biomedical data science | News Center
April 18, 2019 - Cervical cancer subtype increasing in several subpopulations of women
Beta 2 Microglobulin (B2M) Tumor Marker Test: MedlinePlus Lab Test Information

Beta 2 Microglobulin (B2M) Tumor Marker Test: MedlinePlus Lab Test Information

image_pdfDownload PDFimage_print

What is a beta-2 microglobulin tumor marker test?

This test measures the amount of a protein called beta-2 microglobulin (B2M) in the blood, urine, or cerebrospinal fluid (CSF). B2M is a type of tumor marker. Tumor markers are substances made by cancer cells or by normal cells in response to cancer in the body.

B2M is found on the surface of many cells and is released into the body. Healthy people have small amounts of B2M in their blood and urine.

  • People with cancers of the bone marrow and blood often have high levels of B2M in their blood or urine. These cancers include multiple myeloma, lymphoma, and leukemia.
  • High levels of B2M in cerebrospinal fluid can mean that cancer has spread to the brain and/or spinal cord.

A B2M tumor marker test is not used to diagnose cancer. But it can provide important information about your cancer, including how serious it is and how it may develop in the future.

Other names: total beta-2 microglobulin, β2-microglobulin, B2M

What is it used for?

A beta-2 microglobulin tumor marker test is most often given to people who have been diagnosed with certain cancers of the bone marrow or blood. The test may be used to:

  • Figure out the severity of cancer and whether it has spread. This process is known as cancer staging. The higher the stage, the more advanced the cancer is.
  • Predict disease development and guide treatment.
  • See if cancer treatment is effective.
  • See if cancer has spread to the brain and spinal cord.

Why do I need a beta-2 microglobulin tumor marker test?

You may need this test if you have been diagnosed with multiple myeloma, lymphoma, or leukemia. The test can show the stage of your cancer and whether your cancer treatment is working.

What happens during a beta-2 microglobulin tumor marker test?

A beta-2 microglobulin test is usually a blood test, but may also be given as a 24-hour urine test, or as a cerebrospinal fluid (CSF) analysis.

For a blood test, a health care professional will take a blood sample from a vein in your arm, using a small needle. After the needle is inserted, a small amount of blood will be collected into a test tube or vial. You may feel a little sting when the needle goes in or out. This usually takes less than five minutes.

For a 24-hour urine sample, your health care provider or a laboratory professional will give you a container to collect your urine and instructions on how to collect and store your samples. A 24-hour urine sample test usually includes the following steps:

  • Empty your bladder in the morning and flush that urine away. Record the time.
  • For the next 24 hours, save all your urine in the container provided.
  • Store your urine container in the refrigerator or a cooler with ice.
  • Return the sample container to your health provider’s office or the laboratory as instructed.

For a cerebrospinal fluid (CSF) analysis, a sample of spinal fluid will be collected in a procedure called a spinal tap (also known as a lumbar puncture). A spinal tap is usually done in a hospital. During the procedure:

  • You will lie on your side or sit on an exam table.
  • A health care provider will clean your back and inject an anesthetic into your skin, so you won’t feel pain during the procedure. Your provider may put a numbing cream on your back before this injection.
  • Once the area on your back is completely numb, your provider will insert a thin, hollow needle between two vertebrae in your lower spine. Vertebrae are the small backbones that make up your spine.
  • Your provider will withdraw a small amount of cerebrospinal fluid for testing. This will take about five minutes.
  • You’ll need to stay very still while the fluid is being withdrawn.
  • Your provider may ask you to lie on your back for an hour or two after the procedure. This may prevent you from getting a headache afterward.

Will I need to do anything to prepare for the test?

You don’t need any special preparations for a blood or urine test.

You don’t need any special preparations for a CSF analysis, but you may be asked to empty your bladder and bowels before the test.

Are there any risks to the test?

There is very little risk to having a blood or urine test. After a blood test, you may have slight pain or bruising at the spot where the needle was put in, but most symptoms go away quickly.

There is very little risk to having a spinal tap. You may feel a little pinch or pressure when the needle is inserted. After the test, you may get a headache, called a post-lumbar headache. About one in ten people will get a post-lumbar headache. This can last for several hours or up to a week or more. If you have a headache that lasts longer than several hours, talk to your health care provider. He or she may be able to provide treatment to relieve the pain. You may feel some pain or tenderness in your back at the site where the needle was inserted. You may also have some bleeding at the site.

What do the results mean?

If the test was used to find out how advanced your cancer is (cancer stage), the results may show how much cancer is in your body and whether it is likely to spread.

If the B2M test was used to check how well your treatment is working, your results may show:

  • Your B2M levels are increasing. This may mean your cancer is spreading, and/or your treatment is not working.
  • Your B2M levels are decreasing. This may mean your treatment is working.
  • Your B2M levels have not increased or decreased. This may mean your disease is stable.
  • Your B2M levels decreased, but then later increased. This may mean your cancer has come back after you’ve been treated.

If you have questions about your results, talk to your health care provider.

Is there anything else I need to know about a beta-2 microglobulin tumor marker test?

Beta-2 microglobulin tests are not always used as tumor marker tests for cancer patients. B2M levels are sometimes measured to:

  • Check for kidney damage in people with kidney disease.
  • Find out if a viral infection, such as HIV/AIDS, has affected the brain and/or spinal cord.
  • Check to see if disease has advanced in people with multiple sclerosis, a chronic disease affecting the brain and spinal cord.
Tagged with:

About author

Related Articles